×
This post has expired! It was posted more than 90 days ago.
<- Back

148289 - GLP-1RAs: Rethinking Treatment Intensification in People with T2D

  • : Online

 

Optimising glycaemic management is a critical part of patient care, however the glycaemic target will vary depending on an individual patient’s risk versus benefit analysis and their personal priorities and health status. 
This 1hr Category 2 activity, will review how glycaemic targets should be tailored and considered according to patient capabilities and the risk of severe hypoglycaemia, addresses factors that contribute to clinical inertia and considers the options of introducing GLP-1RAs to intensify treatment for people with T2D. This activity will also discuss the safety and efficacy of GLP-1RAs in optimising T2D treatment and on-going management.

Relevance to General Practice

The prevalence of type 2 diabetes (T2D) is increasing in Australia, most likely a result of rising overweight and obesity rates, lifestyle and dietary changes and an ageing population. According to self-reported data, in 2014-15 an estimated one million Australian adults had T2D. Approximately 25% of people over the age of 65 years have diabetes and 50% of older people have prediabetes. 

Learning outcomes
  • Review current recommendations for treatment intensification for people with type 2 diabetes (T2D) who require treatment intensification beyond oral agents
  • Assess when injectable therapy should be considered and appreciate the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in T2D management
  • Recall the indication, safety and efficacy of GLP-1RAs
  • Differentiate between GLP-1RA options available in Australia
  • Delivery
    Title
    148289 - GLP-1RAs: Rethinking Treatment Intensification in People with T2D
    Location
    Duration
    1 hour
    Start Date
    30-Nov-2018
    End Date
    30-Dec-2019
    CPD Points
    1 hour
    Price
    Free
    Location
    Online
    Contact Phone
    Log in into view this field.
    HealthcareLink